IO Biotech, Inc. (IOBT)
2025-06-30 | ||||
|---|---|---|---|---|
| Income taxes expense | 118 | |||
| Income taxes expense | 100 | |||
| Research and development | 16,652 | |||
| General and administrative | 6,518 | |||
| Total operating expenses | 23,170 | |||
| Loss from operations | -23,170 | |||
| Interest expense | 253 | |||
| Interest income | 285 | |||
| Currency exchange loss, net | -374 | |||
| Change in fair value of warrants | 2,587 | |||
| Total other (expense) income, net | -2,929 | |||
| Loss before income tax expense | -26,099 | |||
| Net loss | -26,217 | |||
| Net loss attributable to common shareholders | -26,217 | |||
| Net loss per common share, basic | -0.4 | |||
| Net loss per common share, diluted | -0.4 | |||
| Weighted-average number of shares used in computing net loss per common share, basic | 65,880,914 | |||
| Weighted-average number of shares used in computing net loss per common share, diluted | 65,880,914 | |||